Eric Segal, MD: Diazepam Clinical Utility Regardless of Concomitant Benzodiazepines
The director of pediatric epilepsy at HMN Hackensack University Medical Center provided background on how his data may change how clinicians use diazepam nasal spray.
"The lack of significant changes in side effects in these 2 populations gives further reassurance that this is a safe treatment to give. This is really a game changer for our independent patients.”
Recently presented
Although, among the notable findings, there was a higher proportion of patients who experienced treatment-emergent adverse events (TEAEs) when taking concomitant benzodiazepines (79.8%) than those without (61.5%). The real-world results add more clarity to diazepam’s clinical utility after it was
Segal, director of pediatric epilepsy at HMN Hackensack University Medical Center, feels as though his study serves as an opportunity to change and improve patient practice. In an interview with NeurologyLive, he outlined why the results may change the clinician perspective on prescribing it to their patients, and whether it could potentially lead to more singular prescriptions of diazepam nasal spray by itself.
For more coverage of AES 2020,
REFERENCE
Segal E, Tarquinio D, Miller I, et al. Evaluation of diazepam nasal spray in patients with epilepsy concomitantly using maintenance benzodiazepines: interim analysis from a phase 3, long-term, open-label safety study. Presented at AES 2020 Annual Meeting; December 4–8, 2020. Abstract 337.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Articles
- Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
September 15th 2025
- 2025 Women in Neurology Conference: Educating, Mentoring, and Networking
September 15th 2025
- This Week on NeurologyLive® — September 15, 2025
September 15th 2025
- NeurologyLive® Brain Games: September 14, 2025
September 14th 2025